For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 25,662,855 | |||
| General and administrative | 9,602,351 | |||
| Loss from operations | -35,265,206 | |||
| Interest income | 3,323,855 | |||
| Interest expense | 1,905,310 | |||
| Total other income, net | 1,418,545 | |||
| Net loss | -33,846,661 | |||
| Basic EPS | -0.56 | |||
| Diluted EPS | -0.56 | |||
| Basic Average Shares | 60,056,557 | |||
| Diluted Average Shares | 60,056,557 | |||
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)